Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians

@article{Snow2004LipidCI,
  title={Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians},
  author={Vincenza Snow and M D Aronson and E Rodney Hornbake and Christel Mottur-Pilson and Kevin B. Weiss},
  journal={Annals of Internal Medicine},
  year={2004},
  volume={140},
  pages={644-649}
}
Diabetes mellitus is a leading cause of morbidity and mortality in the United States. Type 2 diabetes mellitus is most common (90% to 95% of persons with diabetes) and affects older adults, particularly those older than 50 years of age. An estimated 16 million Americans have type 2 diabetes, and up to 800000 new diagnoses are made each year (1, 2). Most adverse diabetes outcomes are a result of vascular complications, which are generally classified as microvascular (such as retinopathy… Expand
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
TLDR
This paper focuses on the evidence behind the use of lipid-lowering agents in type 2 diabetes by evaluating the effects of lipid management in primary prevention and secondary prevention in randomized, controlled trials of drug therapy that included patients with diabetes. Expand
Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.
TLDR
Research data suggest that simple strategies combining thiazolidinediones and statins could have complementary effects on CVD risk-factor profiles in diabetes, alongside the ability to control glycemia. Expand
Treating Diabetic Dyslipidemia: A Review of Practical Recommendations Based on Clinical Trials
TLDR
The high cardiovascular risk associated with diabetes mellitus warrants more aggressive lipid-lowering therapy, including reduction of LDL-C, in all patients with DM, and results of the Steno-2 study support HDL-C as a primary target of cardiovascular risk management in patients withDM. Expand
Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists.
TLDR
This study demonstrates suboptimal treatment with statins in patients with type 2 diabetes and cardiovascular risk factors, as demonstrated by the percentage of patients on at least moderate doses of statins. Expand
The management of type 2 diabetes mellitus focus on quality.
TLDR
The purpose of this article is to provide the latest evidence and recommendations to assist primary care physicians in providing quality ambulatory care to individuals who have type 2 diabetes mellitus. Expand
Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia
TLDR
Recent data suggest that lower dosages and newer formulations of niacin can be used safely in diabetic patients with good glycemic control, and lipid goals can be achieved in most patients with diabetes when all available products are considered and, if necessary, used in combination. Expand
Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
  • P. Jones
  • Medicine
  • The American journal of cardiology
  • 2007
TLDR
It is hoped that ongoing trials will demonstrate the clinical outcomes benefits of combination therapy in patients with diabetes, as the combination of a statin and fenofibrate significantly reduced LDL, reduced triglycerides, and increased HDL compared with astatin alone. Expand
Treatment of lipids and type 2 diabetes
TLDR
Some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested. Expand
Dyslipidemia Associated With Diabetes and Insulin Resistance Syndromes
TLDR
The accelerated atherosclerosis seen among patients with type 2 diabetes begins years to decades before the diagnosis of diabetes, which confers the same risk for CHD over a 10-yr period as a prior cardiovascular event. Expand
Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy.
TLDR
There is considerable undertreatment of high- risk patients without an established CVD with lipid-lowering drugs, despite well-established evidence of the benefits of statins in the primary prevention of CVD for high-risk individuals with average cholesterol levels, diabetes mellitus, and in elderly patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus
Diabetes mellitus is a leading cause of morbidity and death in the United States. Type 2 diabetes mellitus accounts for the majority of affected persons (90% to 95%) and affects older adults,Expand
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
TLDR
This paper focuses on the evidence behind the use of lipid-lowering agents in type 2 diabetes by evaluating the effects of lipid management in primary prevention and secondary prevention in randomized, controlled trials of drug therapy that included patients with diabetes. Expand
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care
TLDR
The goals of this paper are to review the literature to evaluate effects of management of hypertension on the complications of type 2 diabetes and to determine optimal blood pressure goals and choice of agents, to provide an evidence base to guide clinicians in setting hypertension treatment goals and priorities. Expand
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
  • G. Bakris, M. Williams, +7 authors J. Sowers
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2000
TLDR
An evidence-based approach is provided, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events to achieve lower blood pressure goals. Expand
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
TLDR
In men with CHD and a low high-density lipoprotein cholesterol level, gemfibrozil use was associated with a reduction in major cardiovascular events in persons with diabetes and in nondiabetic subjects with a high fasting plasma insulin level. Expand
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
TLDR
Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM. Expand
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared. Expand
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
TLDR
It is suggested that cholesterol lowering with simvastatin improves the prognosis of diabetic patients with CHD and the absolute clinical benefit achieved by cholesterol lowering may be greater in diabetic than in nondiabetic patients withCHD because diabetic patients have a higher absolute risk of recurrent CHD events and other atherosclerotic events. Expand
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
TLDR
Compared with similarly dyslipidemic nondiabetic subjects, patients with NIDDM are at markedly increased risk of CHD and this elevated risk can be somewhat reduced by gemfibrozil. Expand
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
TLDR
Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals and was extended to elderly individuals the treatment strategy currently used in middle aged people. Expand
...
1
2
3
...